Reports

Ideas That Generate Results

1. Analyst View

2. Research Methodology

3. Statistical Snapshot - Pregnancies and Chromosomal Abnormalities

4. Overview of US Prenatal Diagnostics Market
     4.1 Introduction
     4.2 Prenatal Diagnostics Industry
            4.2.1 Preliminary Prenatal Testing
            4.2.2 First Trimester Screening
            4.2.3 Second Trimester Screening
            4.2.4 Chorionic Villus Sampling (CVS) Testing
            4.2.5 Amniocentesis Testing

5. US Non-Invasive Prenatal Diagnostics - Market Insight
     5.1 Tests Available in the Market
            5.1.1 MaterniT21 (Sequenom)
            5.1.2 Verifi (Verinata Health)
            5.1.3 Harmony Prenatal Test (Ariosa Diagnostics)
            5.1.4 Panorama (Natera)
     5.2 Current and Future Market Projections to 2017
     5.3 Regulatory Insight
            5.3.1 Current Regulatory Scenario
            5.3.2 Regulatory Authority Perspective
            5.3.3 Diagnostic Test Provider Perspective
            5.3.4 Consumers’ Perspective
            5.3.5 Analyst Inputs

6. Current Technologies in the Market

7. Constraints in NIPD Market

8. Competitive Assessment
     8.1 Ariosa Diagnostics
            8.1.1 Company Overview
            8.1.2 Product Overview
            8.1.3 Strengths and Weaknesses
     8.2 Sequenom
            8.2.1 Company Overview
            8.2.2 Product Overview
            8.2.3 Strengths and Weaknesses
     8.3 Verinata
            8.3.1 Company Overview
            8.3.2 Product Overview
            8.3.3 Strengths and Weaknesses
     8.4 Natera
            8.4.1 Company Overview
            8.4.2 Product Overview
            8.4.3 Strengths and Weaknesses